Summary: Apolipoproteins B and E were determined in 40 patients with type III hyperlipoproteinaemia (familial dysbetalipoproteinaemia) and in 48 patients with other types of hyperlipoproteinaemia matched for cholesterol and triacylglycerols. In type III patients, apolipoprotein E was increased and apolipoprotein B was lower than in other types of hyperlipoproteinaemia. The apolipoprotein E to apolipoprotein B ratio almost completely discriminated between type III and other types of hyperlipoproteinaemia. Assuming a cutoff value of 0.09 for the apolipoprotein E to apolipoprotein B ratio, diagnostic sensitivity was 95% and specificity was 88%. It is concluded that the apolipoprotein E to apolipoprotein B ratio represents the firstline screening quantity of choice for the identification of patients with type III hyperlipoproteinaemia in the clinical laboratory.
FKK κ jv bind normally to apolipoprotein B,E-receptors (5 -7), ' and this accounts for the impaired clearance of rem-However, none of these criteria is compelling. Chonants in type III hyperlipoproteinaemia. However, the lesterol and triacylglycerols may vary widely in and apolipoprotein E2/2 phenotype is much more frequent among type III subjects. Cutaneous xanthomas occur than type III hyperlipoproteinaemia. Only one in 20 in only about 50% of the patients, and the demonapolipoprotein E2/2 homozygotes will actually de-stration of a broad -band in agarose gel electrophovelop type III hyperlipoproteinaemia, the remaining resis of whole plasma is often misleading. Obviously, the most reliable markers for type III hyperlipoproteinaemia are an increased VLDL-cholesterol to plasma triacylglycerol ratio, the demonstration of ß-VLDL, and apolipoprotein E2/2 homozygosity. 1 ) This means that laboratory diagnosis of type III hyperlipoproteinaemia depends on sophisticated methods such as ultracentrifugation and apolipoprotein E phenotyping which are usually available to specialized laboratories only.
On the other hand, there are several points calling for a simple way to recognize type III hyperlipoproteinaemia in the clinical setting. Firstly, affected patients carry a tremendous risk of developing coronary artery disease and peripheral vascular disease. Secondly, the diagnosis of type III hyperlipoproteinaemia has a considerable therapeutic impact. Type III patients usually respond well to the elimination of disease promoting factors and/or to dietary treatment, and once lipoprotein metabolism has been normalized, former type III patients may even be protected from premature atherosclerosis due to the low concentration of LDL found in normolipidaemic E2 homozygotes (1).
It has been known for a long time that apolipoprotein E concentrations are increased in type III hyperlipoproteinaemia (12) , whereas apolipoprotein B is normal or low. Nowdays, both apolipoprotein E and apolipoprotein B can easily be quantified by automated methods. We have therefore studied the relevance of apolipoprotein E and apolipoprotein B determinations to the differential diagnosis of type III hyperlipoproteinaemia.
Materials and Methods

Blood sampling
Fasting blood samples were drawn into tubes containing EDTA • K 2 al a final concentration of 1.5 -2.0 g/1 (Sarstedt, Nurnbrecht, Germany). Plasma was recovered by centrifugation and stored at 4 °C.
Lipoprotein and apolipoprotein analysis
Cholesterol (Monotest, CHOD-PAP) and triacylglycerols (GPO-PAP) were measured using reagents from Boehringer Mannheim (Germany). VLDL-cholesterol was determined by preparative ultracentrifugation at d 20°c = 1.0063 kg/1 (2.35 • 10 8 g · min) as described (13) . High density lipoprotein cholesterol was measured after precipitation of apolipoprotein Bcontaining lipoproteins with sodium phosphotungstic acid and MgCl 2 (13) . LDL-cholesterol was calculated as the difference between total cholesterol and the sum of VLDL-cholesterol and high density lipoprotein cholesterol (13) . ') Homozygosity for apolipoprotein E2 is highly suggestive of type III hyperlipoproteinaemia, but other apolipoprotein E phenotypes do not rule out the disorder.
Apolipoproteins B and E were determined by kinetic nephelometry (Array Protein System, Beckman Diagnostics, Brea, CA). The assay for apolipoprotein B was calibrated with the apolipoprotein calibrator APO CAL from Beckman Diagnostics, which is standardized against the WHO international reference material. The assay for apolipoprotein E was also calibrated using a standard provided by Beckman. Electrophoresis of lipoproteins was carried out as described by Neubeck et al. (14) . Apolipoprptein E phenotyping was performed by isolectric focusing of delipidated VLDL (15) Table 1 contains mean lipid and apolipoprotein concentrations in the two patient groups. As a result of matching, the groups were similar with respect to cholesterol and triacylglycerols. In spite of this, apolipoprotein B was lower and apolipoprotein E was higher in type III subjects than in non-type III subjects. Consequently, the apolipoprotein E/B ratio was different. Figure 1 shows that the apolipoprotein E/B ratio allows almost complete discrimination of the groups. Using a threshold value of 0.09 for the apolipoprotein E/B ratio, type III hyperlipoproteinaemia would be detected with a sensitivity of 95%, the specificity being 88%. If one assumes that the prevalence of type III hyperlipoproteinaemia is 1 in 100 patients with hyperlipidaemia, the predictive value of the positive test (apolipoprotein E/B > 0.09) is 0.07, the predictive value of the negative test is 1.00, and diagnostic efficacy is 0.88.
In plasma, a considerable fraction of apolipoprotein E is associated with triacylglycerol-rich lipoproteins. Therefore, increases in triacyclglycerols are generally attended by increases in apolipoprotein E. In fact, in type III patients as well as in the controls, the apolipoprotein E/B ratio was positively correlated with triacylglycerols, the correlation coefficients being 0.483 and 0.632, respectively. However, as shown in figure 2 , at any given triacylglycerol concentration the apolipoprotein E/B ratio was higher in type III patients than in the control group. Figure 2 also illustrates that if the apolipoprotein E/B cut-off is set in favour of maximal sensitivity, e.g. at 0.07, triacylglycerol concentrations may be disregarded. In contrast, if specificity is to be increased, the apolipoprotein E/B cut-off has to be adjusted for triacyclglycerols, tentative threshold values being 0.09 in samples with triacylglycerols below 5.0 g/1, and 0.2 in samples with higher triacylglycerols. 
Discussion
Our data show that apolipoprotein Ε is markedly increased in type III hyperlipoproteinaemia, while apolipoprotein B is low or normal. This constellation is not only seen in type III hyperlipoproteinaemia, but also in normolipidaemic E2/2 homozygotes, and it relates to the well-documented functional abnormality of apolipoprotein E2 (5-7).
Apart from several rare variants (17 -23) , there are three common alleles at the apolipoprotein E gene locus (ε2, ε3, and ε4), encoding for the isoforms E2, E3, and E4 (24). More than 90% of patients with type III hyperlipoproteinaemia are of the E2/2 phenotype (9) . In vitro, apolipoprotein E2 is defective in binding to apolipoprotein B,E-receptors (5 -7). Since the clearance of both chylomicron and VLDL remnants depends on apolipoprotein E, even normolipidaemic apolipoprotein E2/2 homozygotes accumulate small amounts of remnant particles in the circulation (dysbetalipoproteinaemia). The flux of dietary cholesterol into the liver is decreased and hepatic apolipoprotein Β,Ε-receptors are up-regulated. Therefore, E2 homozygotes have low LDL-cholesterol and apolipoprotein Β concentrations. In contrast, the presence of at least one apolipoprotein E4 allele is associated with high levels of LDL-cholesterol and apolipoprotein Β (1, 9-11). ' . \ In type III hyperlipoproteinaemia, remnant accumulation is largely accentuated by the presence of at least one factor other than apolipoprotein E2 homozygosity, exogenous or genetic. In general, the remnant particles found in type III hyperlipoproteinaemia impose a very high risk of atherosclerosis, β-VLDL from subjects with type III hyperlipoproteinaemia are avidly taken up by macrophages, which are thereby converted into lipid-storing foam cells, one of the key cell types of atherosclerotic lesions (25) . Since type III hyperlipoproteinaemia responds well to the elimination of disease-promoting conditions (1) and to dietary treatment (26) , its recognition is of vital importance for the affected individuals.
Unfortunately, there is hardly any simple and straightforward screening method for type III hyperlipoproteinaemia in the clinical laboratory. Thus, many patients with this disorder have so far remained undiagnosed.
Generally speaking, samples in which both cholesterol and triacylglycerols are about two-to fourfold the normal value are suggestive of type III hyperlipoproteinaemia. However, in routine practice, methods such as ultracentrifugation or apolipoprotein E phenotyping are not available for confirming or rejecting the diagnosis of type III hyperlipoproteinaemia. Therefore, a simple, yet sensitive test is required to identify patients with type III hyperlipoproteinaemia. In the present study, we show that the apolipoprotein E/ apolipoprotein Β ratio almost completely discriminates between type III hyperlipoproteinaemia and other types of hyperlipoproteinaemia with approximately the same concentrations of total cholesterol, triacylglycerols and high density lipoprotein cholesterol. Using a cut-off point of 0.09 for the apolipoprotein E/B ratio, sensitivity and specificity would be 95% and 88%, respectively. Assuming that the prevalence of type III hyperlipoproteinaemia is 1 in 100 patients with hyperlipidaemia, the predictive value of the positive test (apolipoprotein E/B > 0.09) would be 0.07, the predictive value of the negative test would be 1.00 and diagnostic efficacy would be 0.88. These estimates are very close to the characteristics of tests applied to the screening for rare inborn errors of metabolism such as phenylketonuria, cystic fibrosis, hypothyroidism or muscular dystrophies (27) .
Since automated assays for both apolipoprotein Β and apolipoprotein Ε have recently become available, these determinations can conveniently be performed in any clinical laboratory. The values for the apolipoprotein Ε to apolipoprotein Β ratio obtained in this work do, of course, depend on the immunoassay method used. Our apolipoprotein B immuiioassay was calibrated against the WHO international reference material. At present, no such material is available for apolipoprotein E. Therefore, the cut-off values derived here may need adjustment in the future. In the meantime, laboratories using our approach to the screening for type III hyperlipoproteinaemia will have to establish own normal ranges.
The apolipoprotein E to apolipoprotein Β ratio does not replace the classical means of confirming type III hyperlipoproteinaemia, but it may prove suitable as a first line screening parameter for identifying patients in need of additional testing with technically demanding procedures such as ultracentrifugation or apolipoprotein E phenotyping.
